About panitumumab
EGFR-blocking monoclonal antibody
Used for
- Treats certain advanced colorectal cancers that have specific tumor gene characteristics.
Usual adult dose
6 mg/kg by intravenous infusion every 14 days; dosing depends on tumor type and treatment plan.
Common side effects
- Acne-like rash and other skin reactions
- Diarrhea
- Low magnesium and other electrolyte changes
- Infusion reactions
Important warnings
- Used only for eligible tumors; testing for RAS mutations is required.
- Serious skin reactions and infections can occur.
- Monitor electrolytes during treatment and after it ends.
- Can cause severe harm to an unborn baby.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for two months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for two months after the last dose.
Interactions
- No major drug interactions are established; tell the cancer team about all medicines and supplements.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.